In a separate experiment, we performed a WOW-1-binding assay, which is a clone of Fab fragments of antibodies that bind only to active form (high affinity) of integrin β3.
The unique design of the Fab fusion concept used in the library led to not only superior success rate of protein production, but also versatile applications in various high-throughput screening paradigms including protein-protein binding assays as well as cell binding assays, which were not possible for any other existing expression libraries.
Traditional approaches to drug target identification include literature search-based target prioritization and in vitro binding assays which are both time-consuming and labor intensive.
Over the past 30 y competitive folate protein binding assays, which are available in kit form, have supplanted microbiological assays in many clinical laboratories because of their ease of use.
Our assay constitutes a hybridization assay which is fundamentally different than all previously developed hybridization assays, since no denaturation of the duplex DNA is required prior to binding of the ssDNA probe.
The effect of the mutation of rhodopsin "hydrophobic patch" residues on arrestin binding was studied by a retinal release assay, which was based on the observation that arrestin could inhibit the release of retinal from rhodopsin, upon light activation.
The probe and competitor were pooled and 0.87 μl used for each binding/competition assay (which was carried out for 15 min at room temperature).
Similar results were also observed using the microfiltration binding assay, which showed that the circulating FRα is functional.
To assess affinity of AtraPBP1 for pheromone constituents, we used a previously developed binding assay [5], which is based on the separation of bound and unbound ligand by a centrifugal device.
The binding region in hTIM-1 to EBOV GP was mapped by chimeras and mutation assays, which were designed based on structural analysis.
